The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
Boston Scientific forked over $175 million up front for Apama Medical, which is working on a new treatment for afib.
In life sciences companies, collaboration is key. It’s important for operational leaders to partner with finance leaders to consider risks and issues that may…
Illumina Ventures reeled in $130 million in new funding, bringing its genomics-ventured fund to $230 million.
AstraZeneca admitted that some early data for Acerta's BTK inhibitor acalabrutinib was crooked.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.
A team of researchers led by Princeton University has published genetic data related to 44 different human tissue types.
After posting positive results from a midstage test of its oral immunotherapy AR101 last spring, Aimmune Therapeutics will try out its peanut allergy…
The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.
Incyte and Bristol-Myers Squibb/Flexus are set to go to war in the courts over claims that a former scientist stole info around an oncology med.
Roche will pay up to $387 million to license certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.